- Home
- BGI vs LUMO Comparison
BGI vs LUMO Comparison
Compare BGI & LUMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- LUMO
- Stock Information
- Founded
- BGI 1879
- LUMO 2011
- Country
- BGI Canada
- LUMO United States
- Employees
- BGI N/A
- LUMO N/A
- Industry
- BGI
- LUMO Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- LUMO Health Care
- Exchange
- BGI Nasdaq
- LUMO Nasdaq
- Market Cap
- BGI 41.6M
- LUMO 37.4M
- IPO Year
- BGI 2005
- LUMO N/A
- Fundamental
- Price
- BGI $1.59
- LUMO $4.32
- Analyst Decision
- BGI
- LUMO Buy
- Analyst Count
- BGI 0
- LUMO 4
- Target Price
- BGI N/A
- LUMO $9.38
- AVG Volume (30 Days)
- BGI 33.7K
- LUMO 82.6K
- Earning Date
- BGI 12-03-2024
- LUMO 11-07-2024
- Dividend Yield
- BGI N/A
- LUMO N/A
- EPS Growth
- BGI N/A
- LUMO N/A
- EPS
- BGI N/A
- LUMO N/A
- Revenue
- BGI $136,823,177.00
- LUMO $2,205,000.00
- Revenue This Year
- BGI N/A
- LUMO $184.11
- Revenue Next Year
- BGI N/A
- LUMO N/A
- P/E Ratio
- BGI N/A
- LUMO N/A
- Revenue Growth
- BGI 13.70
- LUMO 26.94
- 52 Week Low
- BGI $1.53
- LUMO $1.37
- 52 Week High
- BGI $4.88
- LUMO $4.58
- Technical
- Relative Strength Index (RSI)
- BGI 11.98
- LUMO 55.26
- Support Level
- BGI $1.53
- LUMO $4.30
- Resistance Level
- BGI $2.19
- LUMO $4.39
- Average True Range (ATR)
- BGI 0.16
- LUMO 0.09
- MACD
- BGI -0.05
- LUMO -0.03
- Stochastic Oscillator
- BGI 8.21
- LUMO 32.50
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About LUMO Lumos Pharma Inc.
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.